142 related articles for article (PubMed ID: 36031050)
21. SMAD4-independent activation of TGF-β signaling by MUC1 in a human pancreatic cancer cell line.
Grover P; Nath S; Nye MD; Zhou R; Ahmad M; Mukherjee P
Oncotarget; 2018 Jan; 9(6):6897-6910. PubMed ID: 29467938
[TBL] [Abstract][Full Text] [Related]
22. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
23. MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.
Huang FT; Peng JF; Cheng WJ; Zhuang YY; Wang LY; Li CQ; Tang J; Chen WY; Li YH; Zhang SN
Dig Dis Sci; 2017 Apr; 62(4):944-957. PubMed ID: 28194669
[TBL] [Abstract][Full Text] [Related]
24. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
25. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma.
Tinder TL; Subramani DB; Basu GD; Bradley JM; Schettini J; Million A; Skaar T; Mukherjee P
J Immunol; 2008 Sep; 181(5):3116-25. PubMed ID: 18713982
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia and Transforming Growth Factor β Cooperate to Induce Fibulin-5 Expression in Pancreatic Cancer.
Topalovski M; Hagopian M; Wang M; Brekken RA
J Biol Chem; 2016 Oct; 291(42):22244-22252. PubMed ID: 27531748
[TBL] [Abstract][Full Text] [Related]
27. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ
J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625
[TBL] [Abstract][Full Text] [Related]
28. The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Tréhoux S; Duchêne B; Jonckheere N; Van Seuningen I
Biochem Biophys Res Commun; 2015 Jan; 456(3):757-62. PubMed ID: 25511698
[TBL] [Abstract][Full Text] [Related]
29. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
30. EGFR-mediated carcinoma cell metastasis mediated by integrin αvβ5 depends on activation of c-Src and cleavage of MUC1.
Lau SK; Shields DJ; Murphy EA; Desgrosellier JS; Anand S; Huang M; Kato S; Lim ST; Weis SM; Stupack DG; Schlaepfer DD; Cheresh DA
PLoS One; 2012; 7(5):e36753. PubMed ID: 22586492
[TBL] [Abstract][Full Text] [Related]
31. Identification of FRA-1 as a novel player in pancreatic cancer in cooperation with a MUC1: ERK signaling axis.
Hanson RL; Brown RB; Steele MM; Grandgenett PM; Grunkemeyer JA; Hollingsworth MA
Oncotarget; 2016 Jun; 7(26):39996-40011. PubMed ID: 27220889
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer.
Xu HL; Zhao X; Zhang KM; Tang W; Kokudo N
World J Gastroenterol; 2014 Sep; 20(34):12171-81. PubMed ID: 25232251
[TBL] [Abstract][Full Text] [Related]
33. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Wang K; Baldwin GS; Nikfarjam M; He H
Am J Physiol Gastrointest Liver Physiol; 2019 May; 316(5):G632-G640. PubMed ID: 30844294
[TBL] [Abstract][Full Text] [Related]
34. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer.
Yoneura N; Takano S; Yoshitomi H; Nakata Y; Shimazaki R; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Miyazaki M; Ohtsuka M
Int J Mol Med; 2018 Aug; 42(2):821-830. PubMed ID: 29749431
[TBL] [Abstract][Full Text] [Related]
35. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
36. A tumor specific antibody to aid breast cancer screening in women with dense breast tissue.
Roy LD; Dillon LM; Zhou R; Moore LJ; Livasy C; El-Khoury JM; Puri R; Mukherjee P
Genes Cancer; 2017 Mar; 8(3-4):536-549. PubMed ID: 28680538
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of MUC1 in advanced pancreatic cancer.
Hinoda Y; Ikematsu Y; Horinochi M; Sato S; Yamamoto K; Nakano T; Fukui M; Suehiro Y; Hamanaka Y; Nishikawa Y; Kida H; Waki S; Oka M; Imai K; Yonezawa S
J Gastroenterol; 2003; 38(12):1162-6. PubMed ID: 14714254
[TBL] [Abstract][Full Text] [Related]
38. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression.
Kemper M; Schiecke A; Maar H; Nikulin S; Poloznikov A; Galatenko V; Tachezy M; Gebauer F; Lange T; Riecken K; Tonevitsky A; Aigner A; Izbicki J; Schumacher U; Wicklein D
J Exp Clin Cancer Res; 2021 Jun; 40(1):214. PubMed ID: 34174926
[TBL] [Abstract][Full Text] [Related]
39. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells.
Tréhoux S; Lahdaoui F; Delpu Y; Renaud F; Leteurtre E; Torrisani J; Jonckheere N; Van Seuningen I
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2392-403. PubMed ID: 26036346
[TBL] [Abstract][Full Text] [Related]
40. ERK/BCL-2 pathway in the resistance of pancreatic cancer to anoikis.
Galante JM; Mortenson MM; Bowles TL; Virudachalam S; Bold RJ
J Surg Res; 2009 Mar; 152(1):18-25. PubMed ID: 19062038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
